Robert Corringham

Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose

Michelle Harrison, Eva Obermueller, Nick Maisey et al. · Journal of Clinical Oncology · 2007 · 247 citations · Full text

PARENTERAL ACYCLOVIR THERAPY FOR HERPESVIRUS INFECTIONS IN MAN

Peter J. Selby, Beryl Jameson, J.G. Watson et al. · The Lancet · 1979 · 186 citations

Antiviral Drug Development, Antiviral Therapy, Virology +4

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer

Ewan Brown, Kellie A. Charles, Susan Hoare et al. · Annals of Oncology · 2008 · 180 citations · Full text

Advanced Cancer, Biological Effects, Medicine +10

KETOCONAZOLE VERSUS NYSTATIN PLUS AMPHOTERICIN B FOR FUNGAL PROPHYLAXIS IN SEVERELY IMMUNOCOMPROMISED PATIENTS

Ian Hann, Robert Corringham, M.G.L. Keaney et al. · The Lancet · 1982 · 154 citations

Antifungal Agent, Health Sciences, Immunology +7

A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.

Bertram Wiedenmann, Peter Malfertheiner, Helmut Friess et al. · PubMed · 2008 · 144 citations

Pancreatic Cancer, Phase Ii, Cancer Cachexia +13